These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
27. The Cost-Effectiveness of Intermediate-Acting, Long-Acting, Ultralong-Acting, and Biosimilar Insulins for Type 1 Diabetes Mellitus: A Systematic Review. Saunders H; Pham B; Loong D; Mishra S; Ashoor HM; Antony J; Darvesh N; Bains SK; Jamieson M; Plett D; Trivedi S; Yu CH; Straus SE; Tricco AC; Isaranuwatchai W Value Health; 2022 Jul; 25(7):1235-1252. PubMed ID: 35341688 [TBL] [Abstract][Full Text] [Related]
28. Biosimilar insulins are coming: what they are, what you need to know. Edelman S; Polonsky WH; Parkin CG Curr Med Res Opin; 2014 Nov; 30(11):2217-22. PubMed ID: 25105307 [TBL] [Abstract][Full Text] [Related]
29. SAR342434 - an insulin biosimilar for the treatment of type II diabetes. Hu J; Wang M; Zhao Y Expert Opin Biol Ther; 2018 Nov; 18(11):1107-1112. PubMed ID: 30295083 [TBL] [Abstract][Full Text] [Related]
30. Introduction of biosimilar insulins in Europe. Davies M; Dahl D; Heise T; Kiljanski J; Mathieu C Diabet Med; 2017 Oct; 34(10):1340-1353. PubMed ID: 28608570 [TBL] [Abstract][Full Text] [Related]
31. Biosimilar insulins: guidance for data interpretation by clinicians and users. Heinemann L; Home PD; Hompesch M Diabetes Obes Metab; 2015 Oct; 17(10):911-8. PubMed ID: 25974131 [TBL] [Abstract][Full Text] [Related]
33. New insulins and new insulin regimens: a review of their role in improving glycaemic control in patients with diabetes. Crasto W; Jarvis J; Khunti K; Davies MJ Postgrad Med J; 2009 May; 85(1003):257-67. PubMed ID: 19520878 [TBL] [Abstract][Full Text] [Related]
34. Administration of Biosimilar Insulin Analogs: Role of Devices. Heinemann L; Fritz I; Khatami H; Edelman SV Diabetes Technol Ther; 2017 Feb; 19(2):79-84. PubMed ID: 28118050 [TBL] [Abstract][Full Text] [Related]
36. [New guideline for the treatment of diabetes mellitus type 1]. Hinneburg I Med Monatsschr Pharm; 2012 Feb; 35(2):61-4. PubMed ID: 22400431 [No Abstract] [Full Text] [Related]
37. Diabetes Technology and Therapy in the Pediatric Age Group. Maahs DM; Shalitin S Diabetes Technol Ther; 2018 Feb; 20(S1):S114-S127. PubMed ID: 29437470 [No Abstract] [Full Text] [Related]
38. Formulary Considerations for Insulins Approved Through the 505(b)(2) "Follow-on" Pathway. Rasmussen JT; Ipema HJ Ann Pharmacother; 2019 Feb; 53(2):204-210. PubMed ID: 30122087 [TBL] [Abstract][Full Text] [Related]
39. The advent of biosimilars for the treatment of diabetes: current status and future directions. Polimeni G; Trifirò G; Ingrasciotta Y; Caputi AP Acta Diabetol; 2015 Jun; 52(3):423-31. PubMed ID: 25990669 [TBL] [Abstract][Full Text] [Related]